Chemistry at the Core
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
Built for Patients
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
Driven by Purpose
We are passionate about using our expertise to address the needs of patients with cancer.
Ruth Adams
Vice President, Clinical Operations
Kari Andrews
Clinical
Kristin Andrews, PhD
Chemistry
Alex Balcom, MBA, CPA
Chief Financial Officer
Jim Burgeson
Pharmaceutical Development
Kristi Byrnes
Quality
Matthew Campbell
Pharmaceutical Development
Liz Candido
Operations
Smruti Chaudhari, PhD
Pharmaceutical Development
Sibao Chen, PhD
Pharmaceutical Development
Paula Chubet
Legal
Christopher Cooper, PhD
Pharmaceutical Development
Jess Crespo, CPA
Finance
Steve Critchley
Pharmaceutical Development
Shannon Dauksis, PharmD
Program Management
Rachel DeLaRosa
Clinical
Philip Engel
Information Technology
Jenn Fairbanks
Clinical
Wenzhe Fan, PhD
Pharmaceutical Development
Scott Faulhaber
Clinical Supply Chain
Jesus Garza
Finance
Baudouin Gerard, PhD
Pharmaceutical Development
Tina Gibson
Quality
Nurisha Gobin, PharmD, RPh
Regulatory Affairs
Andrew Havens
Legal
Sophie Higgins
Regulatory Affairs
Joshua Horan, PhD
Vice President, Chemistry
Tina Kehrig
Clinical
Ray Kemper, PhD
Translational Development
Gloria (Glo) Kennedy, RN
Clinical
Jason Kropp
Pharmaceutical Development
Shashank Kulkarni, PhD
Chemistry
Joshua Lance, JD
Legal
Benjamin Lane, PhD
Senior Vice President, Technical Operations
Lidya Le
Clinical
Jeffrey Lee
Information Technology
Megan Lichtenfels, CPA
Finance
Jessie Lin
Vice President, Corporate Strategy & Portfolio Management
Chelcie Lister
Corporate Development
Allison Magnan
Quality
Joseph Magrino, PhD
Biology
Morgan Maiola
Quality
Sowjanya Mangipudi
Clinical
Christian Martin
Translational Development
Nathan McConarty, JD
Legal
Stephen McNamara
Finance
Scot Mente, PhD
Chemistry
Matthew Metivier
Senior Vice President,
Human Resources
Human Resources
Ashlin Miller, PharmD
Program Management
Deb Miller, PhD, JD
Chief Legal Officer
Tuan Minh Nguyen, PhD
Biology
Darlene Noci, ALM
Chief Development Officer
Marco Palencia
Clinical
Henry Pelish, PhD
Senior Vice President, Drug Discovery
James Porter, PhD
Chief Executive Officer
Bob Prytko
Pharmaceutical Development
Gosia Riley
Clinical
José Rios Lizarraga, PhD
Pharmaceutical Development
Amy Rochford
Clinical
Mikhaila Ruth
Human Resources
Prabjyot Sachdev
Corporate Development
Manoj Samant, PhD
Clinical
Danieska Sandino
Clinical
Christine Schneeberg
Clinical Supply Chain
Maureen Secord
Pharmaceutical Development
Jacob Sizemore, PhD
Pharmaceutical Development
Greg Smith
Regulatory Affairs
John Soglia, PhD
Senior Vice President, Translational Development
Kevin Staffin
Quality
Yuting Sun, PhD
Biology
Wint Swe
Clinical
Anupong Tangpeerachaikul, PhD
Biology
Christopher Turner, MD
Chief Medical Officer
Vivek Upadhyay, MD
Clinical
Virginia Vetter
Regulatory Affairs
Brenda Vienneau, CPA, CMA
Finance
Michael Walsh, PhD
Biology
Stacia Wegst-Uhrich, PhD
Pharmaceutical Development
Carla Whalen
Human Resources
Lindsey Wilson
Clinical
Perrin Wilson, PhD
Senior Vice President,
Business Development & Strategy
Business Development & Strategy
Jimmy Yung
Finance
Viola Zhu, MD, PhD
Clinical
Fareya Zubair
Regulatory Affairs
Emily Drabant Conley, PhD
Chief Executive Officer, Renasant Bio
Gary Gilliland, MD, PhD
Independent Board Member
Andrew A. F. Hack, MD, PhD
Managing Director, Bain Capital Life Sciences
Michael Meyers, MD, PhD
Chief Medical Officer, Flare Therapeutics
Joseph Pearlberg, MD, PhD
VP of Scientific Affairs, Deerfield Management
Anna Protopapas
Independent Board Member
Matthew D. Shair, PhD
Founder, Head Scientific Advisor
Sapna Srivastava, PhD
Independent Board Member
Cameron Wheeler, PhD
Partner, Deerfield Management
Read the latest news
Apr 08, 2024
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Mar 05, 2024
